Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Press Releases


 
Press Releases
  Date Title and Summary View
Jul 19, 2017
LA JOLLA, Calif., July 19, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at the price to the public of $0.91 per share.  Regulus has granted the und...
Jul 19, 2017
LA JOLLA, Calif., July 19, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.  In connection with th...
Jun 13, 2017
LA JOLLA, Calif., June 13, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the promotion of Dr. Mark Deeg to Chief Medical Officer. Dr. Deeg joined Regulus in April 2017 as Vice President of Translational Med...
Jun 12, 2017
LA JOLLA, Calif., June 12, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced updates to its pre-clinical and clinical development programs. "We are squarely f...
Jun 1, 2017
LA JOLLA, Calif., June 1, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Pascale Witz was elected to the Company's board of directors at its Annual Meeting of Stockholders held earlier today. ...
May 4, 2017
LA JOLLA, Calif., May 4, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the three months ended March 31, 2017.  The Company also announced a corporate restructuring plan to streamline it...
Apr 27, 2017
LA JOLLA, Calif., April 27, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide first quarter 2017 financial results on Thursday, May 4, 2017 after the market closes. ...
Mar 28, 2017
LA JOLLA, Calif., March 28, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul C. Grint, M.D., President and Chief Executive Officer of Regulus, will present a company overview at the 16th Annual Needh...
Mar 2, 2017
LA JOLLA, Calif., March 2, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and full year ended December 31, 2016 and provided a summary of corporate highlights and pipe...
Feb 23, 2017
LA JOLLA, Calif., Feb. 23, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will release fourth quarter and full year 2016 financial results on Thursday, March 2, 2017 after the market closes. ...
Page:
1
... NextLast
= add release to Briefcase